Perseus Proteomics (TSE:4882) Other Current Payables: 円25.9 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4882 Perseus Proteomics Inc TSE:4882
57 GF Score
Price 円151.00
GF Value 円440.02
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Perseus Proteomics Other Current Payables?

Perseus Proteomics TSE:4882 +1.34% 57 Other Current Payables is 円25.9 Mil as of Mar. 2026. GuruFocus rates TSE:4882 with a GF Score™ of 57/100 and a GF Value™ of 円440.02 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Perseus Proteomics's Other Current Payables for the quarter that ended in Mar. 2026 was 円25.9 Mil.

Perseus Proteomics's quarterly Other Current Payables declined from Mar. 2025 (円61.0 Mil) to Sep. 2025 (円51.6 Mil) and declined from Sep. 2025 (円51.6 Mil) to Mar. 2026 (円25.9 Mil).

Perseus Proteomics's annual Other Current Payables increased from Mar. 2024 (円53.5 Mil) to Mar. 2025 (円61.0 Mil) but then declined from Mar. 2025 (円61.0 Mil) to Mar. 2026 (円25.9 Mil).

Perseus Proteomics Other Current Payables Related Terms

Perseus Proteomics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Perseus Proteomics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perseus Proteomics Other Current Payables Chart

Perseus Proteomics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only 114.57 54.00 53.47 61.01 25.90

Perseus Proteomics Semi-Annual Data
Mar18 Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.47 74.59 61.01 51.65 25.90
TSE:4882
57GF Score
Perseus Proteomics Inc TSE:4882
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perseus Proteomics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of 円25.9 Mil mean?
Perseus Proteomics (TSE:4882) has a Other Current Payables of 円25.9 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Perseus Proteomics and its competitors.
Is Perseus Proteomics' Other Current Payables too high?
Perseus Proteomics' current Other Current Payables is 円25.9 Mil. Overall, Perseus Proteomics has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' Other Current Payables compare to LLY and JNJ?
Perseus Proteomics' Other Current Payables of 円25.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Perseus Proteomics and its competitors. Perseus Proteomics's current Other Current Payables is 円25.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円440.02, compared to a current price of 円151.00 — trading 65.7% below its estimated fair value. The current Other Current Payables is 円25.9 Mil. Perseus Proteomics' overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current Other Current Payables is 円25.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Perseus Proteomics (TSE:4882) Overvalued in 2026?

Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued. The current stock price of 円151.00 is trading 65.7% below its estimated GF Value™ of 円440.02. GuruFocus considers Perseus Proteomics to be Significantly Undervalued.

Key valuation signals for TSE:4882:

  • Other Current Payables: 円25.9 Mil
  • GF Value™: 円440.02 vs. price of 円151.00 (65.7% below fair value)
  • GF Score™: 57/100 with 2 warning signs

No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Perseus Proteomics Business Description

Address 30-1 Hakozakicho, Nihonbashi, Chuo-ku, AiNihombashi EAST 3rd floor, Tokyo, JPN, 103-0015
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
57GF Score

Get the complete analysis for TSE:4882

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円151.00
Price
円440.02
GF Value